RECQL1 siRNA
Alternative Names: RECQL1-siRNALatest Information Update: 11 Jul 2024
At a glance
- Originator GeneCare Research Institute
- Class Antineoplastics; Small interfering RNA
- Mechanism of Action RecQ helicase inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 15 Jul 2020 Solasia enters into an Option Agreement for RECQL1 siRNA with GeneCare Research Institute
- 14 Apr 2008 Preclinical trials in Cancer in Japan (Parenteral), prior to April 2008 (Solasia Pharma pipeline, June 2024)
- 14 Apr 2008 Adverse event and pharmacodynamics data from preclinical trials in Cancer released by GeneCare Research Institute